Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF
NCT04684212 · Brian O'Neill MD · NA · withdrawn · last registry update 2025-11-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of Funding” | – | Registry record, Brian O'Neill MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-21Also stopped (terminated): University Health Network, Toronto, Fibrinogen + PCC + Frozen Plasma (NCT04534751)
- 2026-10-07Results posted on the registry: Instituto Grifols, S.A., Plasma-derived AT-III concentrate (NCT00319228)
- 2026-10-07Also stopped (terminated): Instituto Grifols, S.A., Plasma-derived AT-III concentrate (NCT00319228)
- 2026-10-05Also stopped (terminated): Pfizer, PF-06838435 (formerly SPK-9001) (NCT03307980)
- 2026-08-14Results posted on the registry: Pfizer, PF-06741086 (NCT03938792)
- 2026-08-05Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran + Aspirin (NCT07746882)
- 2026-07-31Results posted on the registry: Spur Therapeutics, verbrinacogene setparvovec (NCT05164471)
- 2026-07-31Also stopped (terminated): Spur Therapeutics, verbrinacogene setparvovec (NCT05164471)
- 2026-07-24Also stopped (terminated): AstraZeneca, Ceralasertib + Drug X (NCT06929260)
- 2026-06-25Also stopped (terminated): Octapharma, Octaplex (NCT04867837)
- 2026-06-24Results posted on the registry: SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-06-24Also stopped (terminated): SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-05-19Results posted on the registry: Massachusetts General Hospital, Rivaroxaban + Warfarin (NCT03702582)
- 2026-05-18Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), ALG-097558 + Dabigatran (NCT06945276)
- 2026-05-13Phase 3 first posted: Cardiocentro Ticino, Clopidogrel + Ticagrelor (NCT07582835)
- 2026-05-12Also stopped (withdrawn): Bayer, Nurandociguat + Rosuvastatin (NCT07515339)
- 2026-05-12Results posted on the registry: Intermountain Health Care, Inc., Dabigatran Etexilate + Warfarin (NCT03061006)
- 2026-04-08Results posted on the registry: Ethicon, Inc., EVARREST® Fibrin Sealant Patch (NCT03255174)
- 2026-03-06Phase 3 first posted: Sunnybrook Health Sciences Centre, Edoxaban 15 mg + Aspirin or clopidogrel (NCT07454707)
- 2026-03-04Results posted on the registry: GATT Technologies BV, TachoSil (NCT05385952)
- 2026-02-06Results posted on the registry: Lumosa Therapeutics Co., Ltd., LT3001 drug product + Placebo (NCT04809818)
- 2026-01-13Phase 3 first posted: Ain Shams University, Melatonin group + Midazolam group (NCT07336095)
- 2026-01-09Results posted on the registry: Boehringer Ingelheim, Zongertinib + Dabigatran-etexilate (NCT06504862)
- 2025-12-10Also stopped (terminated): CSL Behring, BE1116 + Placebo (NCT05568888)
- 2025-11-10Results posted on the registry: CSL Behring, BE1116 + Placebo (NCT05568888)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision